These observation show that increased expression of HER2 wt only moderately increases intrinsic resistance of ER+/HER2+ breast cancer cells to endocrine therapy, supporting the notion that intrinsic resistance to ERα-targeting drugs in ER+/HER2+ breast cancer patients might often be driven by HER2 mutants. The gene discussed is ERBB2; the disease is breast carcinoma.